Increasing complexity of modern therapeutics, growing outsourcing trends, a rise in the demand for advanced treatment options, growing regulatory complexities, increasing collaborations, and expanding drug delivery technologies are promoting the market growth.
The drug delivery CDMO services refer to the contract services provided by the specialised organizations for the development, manufacturing, and optimization of the drug delivery systems. They help in preformulation studies, formulation development, process development, product analysis, clinical trials, manufacturing, and packaging. This promotes the development of oral drug delivery, injectable formulations, oncology drugs, controlled and sustained release, biologic delivery, nanotechnology-based delivery, ophthalmic delivery, and pulmonary delivery systems.
Global Market Growth
The global drug delivery CDMO services market size was estimated at USD 246 billion in 2025 and is predicted to increase from USD 268.39 billion in 2026 to approximately USD 587.74 billion by 2035, expanding at a CAGR of 9.1% from 2026 to 2035.
The Road Ahead: The Growth Opportunities Unleashed
- The growth in the chronic disease burden in the U.S. is increasing the demand for drug delivery CDMO services for the development of patient-friendly drug delivery systems.
- Growing focus on oncology and rare diseases is driving the adoption of these services for the development of high-potency and complex drugs.
- Growing patent expirations are also increasing the outsourcing trends, promoting the use of drug delivery CDMO services.
- A rise in the use of novel drug delivery systems and biologics is also increasing the use of these services.
- Expanding technological innovations and a rise in the demand for advanced manufacturing solutions are also increasing their collaborations.
- Increasing demand for sterilized and specialized capabilities is also increasing their use.
The graph represents a comparison between the estimated cases of cancer deaths and new cases in the U.S. for the year 2026. It indicates that there will be a rise in the cancer burden, which will drive the demand for new diagnostics and treatment options. This, in turn, will promote the adoption of drug delivery CDMO services for their faster and optimized development, which will ultimately enhance the market growth.
Market Segmentation Overview
- By service type, the manufacturing services segment accounted for the highest revenue share of 45% of the U.S. drug delivery CDMO services market in 2025, due to increased demand for new formulations and therapies. The growth in the outsourcing trends and demand for expertise has also increased their use. The increased manufacturing of complex drug delivery systems and complex production also promoted their use.
- By drug type, the small molecule drugs segment contributed the biggest revenue share of 55% of the U.S. drug delivery CDMO services market in 2025, due to growth in their approval rates. Increased demand for their generic versions also increased the adoption of the drug delivery CDMO services. The growth in the applications also increased their outsourcing for large-scale production.
- By end-user, the pharmaceutical companies segment held the largest revenue share of 60% of the U.S. drug delivery CDMO services market in 2025, due to growth in investments in advanced drug delivery technologies. The large-scale manufacturing of the complex drug formulation also increased the use of drug delivery CDMO services. The presence of regulatory expertise also increased new collaborations.
- By technology type, the polymeric systems segment held a major revenue share of 30% of the U.S. drug delivery CDMO services market in 2025, due to their enhanced safety, stability, and compatibility. This increased the use of drug delivery CDMO services for their large-scale manufacturing. The regulatory expertise and affordable delivery platforms also attracted the clients.
Regional Analysis
The U.S. drug delivery CDMO services market held 30% share in 2025 and is expected to show lucrative growth during the forecast period, due to the presence of robust pharmaceutical and biotechnology companies. This increased the development of advanced therapies, biologics, and complex formulations, driving the adoption of the drug delivery CDMO services. High R&D investments and funding also increased innovation and clinical trials, which increased their use, where the growth in the chronic disease burden also enhanced the market growth.
The Power Players: Companies Dominating the U.S. Market
Thermo Fisher Scientific dominated the market with its Accelerator platform and end-to-end services, where Catalent, Inc., was its closest competitor, which offered advanced delivery technologies. West Pharmaceutical Services, Inc. also sustained its position by offering self-injection systems, where Simtra BioPharma Solutions also maintained its position by providing sterile injectable pharmaceuticals.
Segments Covered in the Report
By Service Type
- Development Services
- Formulation Development
- Analytical Testing
- Process Development
- Manufacturing Services
- Commercial Manufacturing
- Clinical Manufacturing
- Fill and Finish Services
- Packaging Services
- Primary Packaging
- Secondary Packaging
- Others (e.g., Regulatory Affairs)
By Drug Type
- Small Molecule Drugs
- Oral Solid Dosage Forms
- Injectable Dosage Forms
- Topical Drugs
- Biologics
- Monoclonal Antibodies
- Vaccines
- Gene and Cell Therapy Products
- Others (e.g., Biosimilars)
By End-user
- Pharmaceutical Companies
- Innovator Companies
- Generic Companies
- Biotechnology Companies
- Emerging Biotech
- Established Biotech
- Others (e.g., Contract Research Organizations)
By Technology
- Liposome Technologies
- Liposomal Drug Delivery
- Nanoparticle-based Delivery
- Polymeric Systems
- Microneedles
- Others (e.g., Transdermal Patches)
